Amrad halts buyback during Avexa spin-out
Thursday, 01 July, 2004
Amrad (ASX:AML) has halted its share buy-back program while it readies itself to spin out its anti-infectives program.
The process will allow the company to calculate the entitlements of shareholders so that shares can be distributed into the new company, Avexa, during the demerger. Amrad shareholders will receive shares in Avexa on a pro rata basis according to their holdings in Amrad on the record date for the offer.
The Amrad share buy-back program will continue once the record date has passed, the company said.
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
Life expectancy gains are slowing, study finds
Life expectancy at birth in the world's longest-living populations has increased by an...
Towards safer epilepsy treatment for pregnant women
New research conducted in organoids is expected to provide pregnant women with epilepsy safer...
